To identify prognostic factors and establish a nomogram for predicting overall survival in HBsAg-positive cervical cancer patients.
Approach:
Validation: Internal validation was conducted to assess the reliability of the nomogram using the bootstrap resampling method.
Key Findings:
The nomogram achieved a Harrell’s C-index of 0.817 (95% CI, 0.762–0.873), outperforming the FIGO staging system's C-index of 0.700 (95% CI, 0.637–0.764, P < 0.001).
Interpretation:
The study established a nomogram for preliminary prognostic evaluation of overall survival in HBsAg-positive cervical cancer patients, indicating its potential utility over the FIGO staging system.
Limitations:
The study is retrospective and may be subject to selection bias.
Further validation of the nomogram is required before clinical application.
Conclusion:
The nomogram provides a more accurate prognostic tool for HBsAg-positive cervical cancer patients, pending further validation.
A targeted radiopharmaceutical improves CAR T activity in neuroblastoma models, engineered Tregs suppress allergic asthma, and new gene therapy platforms target MMA and the brain
